Lexicon Pharmaceuticals Delivers $0.00 Q1 EPS, Beats $0.04 Loss Estimate
Lexicon Pharmaceuticals reported Q1 EPS of $0.00, surpassing the Zacks Consensus Estimate of a $0.04 loss and improving from a $0.07 loss in Q1 2025. The result represents a 100% year-over-year swing in quarterly EPS performance.
1. Q1 EPS Performance
Lexicon Pharmaceuticals reported break-even EPS of $0.00 for the quarter ended March 31, exceeding the Zacks Consensus Estimate of a $0.04 loss and improving from a $0.07 loss in Q1 2025.
Related News
BP
BP Raises Indonesian PSCs to 11 with Bintuni, Drawa and 49% Barong Stake
BP•
TGT
Target Raises Full-Year Sales Outlook to 4% After Q1 Revenue Jumps 6.7%
TGT•
VZLA
Vizsla Silver Taps 20-Year Veteran Hernandez as VP Exploration, Promotes Velador
VZLA•
FDS
Nvidia Q1 Revenue Soars 85% to $81.6B as Buyback Approved
FDS•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
Sources
FZ